Drug · CHEMBL428647
PACLITAXEL
7 sourcespipelines-2026-09-18-0.3.1
Download JSON
Cite this record
ConductScience Library. PACLITAXEL. Drugs and targets, record CHEMBL428647. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL428647
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Abraxane, Apealea, Apexelsin, Naveruclif, Pacitaxel, Paclitaxel component of abi 007, Paclitaxel component of abraxane, Paclitaxel component of nab-, Paclitaxel component of oraxol, Paxene, Pazenir, Taxol, Taxol 100, Zisu
- ChEMBL
- Other names
(-)-PACLITAXEL, (-)-paclitaxel, .BETA.-(BENZOYLAMINO)- .ALPHA.-HYDROXY-, 10.BETA.,13.ALPHA.- HEXAHYDROXY-, 4,10-DIACETATE 2- BENZOATE,13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE, 5.BETA.,20-EPOXY-1,2.ALPHA.,4,7.BETA., 6,12B-BIS(ACETYL OXY)-12-(BENZOYLOXY)- 2A,3,4,4A,5,6,9,10,11,12,12A,12B,- DODECAHYDRO-4,11- DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO- 7,11-METHANO- 1H-CYCLODECA[3,4]BENZ[1,2-B]OXET-9-YL ESTER, 7 EPI TAXOL, 7-EPI-TAXOL, ABI-007, ABRAXANE, APEALEA, APEXELSIN, BMS 181339-01, BMS-181339-01, BRIS TAXOL, CAPXOL, CHEMBL428647, CYCLOPAX, Capxol, Cyclopax, DHP 107, DHP-107, EBETAXEL, EMPAC, ENDOTAG 1, Ebetaxel, Empac, Endotag 1, GENAXOL, GENETAXYL, GENEXOL, GENEXOL-PM, Genaxol, Genetaxyl, Genexol, Genexol-pm, INTAXEL, Intaxel, LEP-ETU, Lep-etu, MBT 0206, MBT-0206, MITOTAX, Mitotax, NAVERUCLIF, NK 105, NK-105, NSC 125973, NSC-125973, NSC125973, ONCOGEL, ONXAL, ONXOL, Oncogel, Onxal, Onxol, PACITAXEL, PACLIEX, PACLITAXEL (TAXOL), PACLITAXEL (TAXUS CANADENSIS), PACLITAXEL COMPONENT OF ABI 007, PACLITAXEL COMPONENT OF ABI-007, PACLITAXEL COMPONENT OF ABRAXANE, PACLITAXEL COMPONENT OF NAB-, PACLITAXEL COMPONENT OF ORAXOL, PACLITAXELANZATAXTAXOLTAXOL (REGISTERED TRADEMARK)7,11-METHANO-5H-CYCLODECA[3,4]BENZ[1,2-B]OXETE,BENZENEPROPANOIC ACID DERIV.BENZENEPROPANOIC ACID, PACLITAXOL, PAXENE, PAZENIR, PLAXICEL, PRAXEL, Pacliex, Paclitaxel (taxus canadensis), Paclitaxol, Plaxicel, QW-8184, SHANGHAI FUDAN-ZHANGJIANG, TAXALBIN, TAXOL, TAXOL 100, TAXOL A, TAXUS, TAXUS LIBERTE, TAXUS STENT, TOCOSOL PACLITAXEL, Taxalbin, Taxol, Taxol a, Taxus, Taxus liberte, Taxus stent, Tocosol paclitaxel, YEWTAXAN, Yewtaxan, ZISU, [2AR- [2A.ALPHA.,4.BETA.,4A.BETA.,6.BETA.,9.ALPHA.(ALPHA. R*,.BETA.S*),11.ALPHA.,12.ALPHA.,12A.ALPHA.,12B.ALPHA.]]-TAX-11-EN-9-ONE
- ChEMBL
- Open Targets' highest stage
- Approval, for 11 of its 266 diseases, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets15
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TUBA1A | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/7846 |
| TUBA1B | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/10376 |
| TUBA1C | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/84790 |
| TUBA3C | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/7278 |
| TUBA3E | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/112714 |
| TUBA4A | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/7277 |
| TUBB | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/203068 |
| TUBB1 | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/81027 |
| TUBB2A | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/7280 |
| TUBB2B | Tubulin | Tubulin inhibitor | INHIBITOR | https://conductscience.org/library/genes/347733 |
1 to 10 of 15Source ChEMBL
See all 15 targetsDiseases266
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| breast cancer | Approval | DailyMed, PMDA and TTD | 758 | 751 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| non-small cell lung carcinoma | Approval | DailyMed and EMA Human Drugs | 623 | 608 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| ovarian cancer | Phase 3 | ClinicalTrials.gov | 249 | 246 | https://conductscience.org/library/drugs?q=MONDO_0008170 |
| malignant pancreatic neoplasm | Phase 3 | ClinicalTrials.gov and TTD | 197 | 196 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| pancreatic neoplasm | Approval | EMA Human Drugs | 199 | 195 | https://conductscience.org/library/drugs?q=MONDO_0021040 |
| esophageal squamous cell carcinoma | Phase 3 | ClinicalTrials.gov | 178 | 178 | https://conductscience.org/library/drugs?q=MONDO_0005580 |
| gastric cancer | Phase 3 | ClinicalTrials.gov | 171 | 171 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| triple-negative breast carcinoma | Phase 3 | ClinicalTrials.gov | 157 | 157 | https://conductscience.org/library/drugs?q=MONDO_0005494 |
| fallopian tube cancer | Phase 3 | ClinicalTrials.gov | 148 | 148 | https://conductscience.org/library/drugs?q=MONDO_0002158 |
| primary peritoneal carcinoma | Phase 3 | ClinicalTrials.gov | 146 | 146 | https://conductscience.org/library/drugs?q=MONDO_0015686 |
1 to 10 of 266Source Open Targets
See all 266 diseasesTrials3,691
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 148 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 418 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | Phase 3 | 4,994 | 2019-09-04 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT00093795 | Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | Phase 3 | 4,894 | 2017-12-12 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | Phase 3 | 4,804 | 2018-01-05 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT00011986 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Phase 3 | 4,312 | 2016-04-19 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT00041119 | Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer | Phase 3 | 3,871 | 2017-05-18 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT00070564 | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | Phase 3 | 3,294 | 2017-04-17 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | Phase 3 | 3,270 | 2020-09-23 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | Phase 3 | 2,199 | 2024-08-21 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT00014222 | Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | Phase 3 | 2,104 | 2020-03-10 | paclitaxel | Its name | ClinicalTrials.gov |
| NCT00129389 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | Phase 3 | 1,925 | 2019-07-12 | paclitaxel | Its name | ClinicalTrials.gov |
1 to 10 of 3,691
See all 3,691 trialsComparisons in its trials637
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause | 364 of 618 | 3,780 of 4,661 | 5,279 | NCT05834348 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause | 48 of 1,622 | 61 of 1,628 | 3,250 | NCT01275677 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events | 31 of 1,615 | 96 of 1,625 | 3,240 | NCT01275677 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: deaths from any cause | 58 of 1,098 | 72 of 1,101 | 2,199 | NCT03498716 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: Number of Participants With Adverse Events (AE) | 1,074 of 1,084 | 1,090 of 1,093 | 2,177 | NCT03498716 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: serious adverse events | 173 of 1,084 | 280 of 1,093 | 2,177 | NCT03498716 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: Overall Survival (OS) Event | 40 of 974 | 31 of 951 | 1,925 | NCT00129389 | Trial comparisons |
| Arm A: FAC vs Arm B: FAC-wP: deaths from any cause | 40 of 974 | 31 of 951 | 1,925 | NCT00129389 | Trial comparisons |
1 to 10 of 637
See all 637 comparisons in its trialsPapers from its trials1,975
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Verbal Learning | 2 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL428647
GET https://conductscience.org/api/drugs/v1/CHEMBL428647/diseases?page=2